Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?
- 7 July 2011
- journal article
- research article
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 285 (2) , 499-503
Abstract
Objective To evaluate the disease control rate (DCR) in heavily pretreated and relapsed ovarian cancer patients re-challenged with a weekly paclitaxel schedule and to establish whether a correlation between dose intensity, progression-free interval (PFI) and overall survival (OS) exists. Methods Retrospective data were collected from 30 heavily pretreated metastatic ovarian cancer patients who received 80 mg/m2/week paclitaxel regimen. Results The treatment was well tolerated and showed a DCR in 70% of the patients, with only one case of grade 3 hematological toxicity. One patient (3%) showed a complete response, 15 patients (50%) a partial response and five patients (17%) a stabilization of their disease. The regimen was mostly used as a fourth-line chemotherapy (range 2–7). The median dose intensity in responding patients was 57.5 mg/m2/week and in those with progressive disease 49.7 mg/m2/week. (p = 0.20). PFI and OS were increased in the responder patient groups with a log-rank test of 25.64 (p < 0.001) and 15.10 (p = 0.0001), respectively. Conclusions Weekly administration of paclitaxel was active and well tolerated as a salvage therapy for heavily pretreated ovarian cancer patients.Keywords
This publication has 19 references indexed in Scilit:
- Decreased dose density of standard chemotherapy does not compromise survival for ovarian cancer patientsInternational Journal of Gynecological Cancer, 2008
- Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancerGynecologic Oncology, 2006
- Kallikrein 4 is associated with paclitaxel resistance in ovarian cancerGynecologic Oncology, 2004
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancerGynecologic Oncology, 2004
- Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancerInternational Journal of Gynecological Cancer, 2003
- Theoretical Concepts and the Emerging Role of Taxanes in Adjuvant TherapyThe Oncologist, 2001
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI: Journal of the National Cancer Institute, 2000
- Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancerEuropean Journal of Cancer, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996